Ending the Compounding Era: How FDA Scrutiny of SYD-101 Could Reshape Childhood Myopia Care

DEL MAR, Calif. – September 24, 2026 – The intersection of global commerce and public health is rarely as stark as it is in the rapidly escalating crisis of pediatric progressive myopia (PPM). A degenerative disease that is quietly reshaping the global demographic landscape, PPM currently affects nearly one-third of children worldwide. By 2050, prevalence is projected to exceed a staggering 740 million cases. Yet, in the United States, the commercial supply chain for treating this impending epidemic remains stubbornly tethered to an unstandardized, off-label regulatory gray area.

That dynamic is now on the precipice of a seismic shift. Sydnexis, Inc., a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has scheduled an Advisory Committee meeting—complete with an Open Public Hearing—for October 30, 2026. The mandate: to review the New Drug Application (NDA) for SYD-101, a proprietary low-dose atropine formulation designed to slow the progression of childhood myopia.

For market strategists and healthcare policy analysts, this upcoming hearing represents far more than a routine regulatory checkpoint. It is a critical test of whether the FDA will validate preventive pediatric endpoints established over two decades ago, and whether the U.S. will finally transition from a fragmented network of compounding pharmacies to a de-risked, commercially standardized pharmaceutical supply chain.

The Compounding Dilemma and Supply Chain Vulnerabilities

To understand the commercial stakes of the October advisory panel, one must examine the precarious state of current myopia care in the United States. Because there are currently zero FDA-approved pharmaceutical options to slow the progression of PPM, clinicians are forced to rely on compounding pharmacies to mix low-dose atropine drops for pediatric patients.

From a supply chain and risk-management perspective, this reliance is fraught with systemic vulnerabilities. Compounded atropine suffers from a well-documented "pH paradox." To make the acidic drops tolerable for children, compounders routinely dilute commercial atropine to a neutral pH. However, at a neutral pH, atropine rapidly hydrolyzes into tropic acid—a degradant with zero antimuscarinic activity that fails to arrest axial elongation in the eye.

Industry audits have repeatedly exposed the fallout of this chemical instability. Independent analyses of U.S. compounded formulations have revealed that a quarter of samples fail to meet minimum potency standards after just 30 days, with some dropping to 70% of their labeled active drug. Furthermore, the dilution process often compromises the antimicrobial preservatives, introducing severe contamination risks during chronic, multi-month home use.

An FDA approval for SYD-101 would effectively end this era of unstandardized care, introducing a rigorously evaluated, shelf-stable, and precisely dosed therapeutic. It represents the ultimate de-risking of a critical pediatric supply chain, shifting the market from out-of-pocket, variable-quality local compounding to a standardized, reimbursable pharmacy benefit.

A Regulatory Stand-Off: The Path to the Advisory Committee

Sydnexis's journey to the October 30 hearing has been a masterclass in regulatory resilience and strategic maneuvering. The scheduling of this Advisory Committee under the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is the direct result of a rare and aggressive administrative appeal.

In October 2025, the FDA issued a Complete Response Letter (CRL) to Sydnexis regarding SYD-101. The agency did not dispute the drug's safety, nor did it cite any manufacturing deficiencies. In fact, the FDA conceded that the Phase 3 STAR trial achieved its prespecified primary endpoint with statistical significance. Instead, the rejection hinged on a subjective interpretation of "clinical meaningfulness"—specifically, whether the absolute magnitude of the treatment effect across the entire unstratified population was sufficient to warrant approval.

Rather than initiating a costly, multi-year secondary trial, Sydnexis executed a Formal Dispute Resolution Request (FDRR) to the FDA’s Office of Specialty Medicine. The company successfully argued that the trial's primary endpoint was the exact threshold established and endorsed by the FDA’s own advisory committee in 2003. The granting of this appeal sets the stage for a highly anticipated public debate on regulatory consistency.

“We welcome the opportunity for a thorough, science-based discussion on SYD-101 and the totality of evidence supporting its use in pediatric progressive myopia,” said Perry Sternberg, Chief Executive Officer of Sydnexis. “The STAR trial met its prespecified primary and key secondary endpoints, and those results should be considered within the broader clinical context of a progressive disease in which the goal of treatment is to prevent irreversible myopia from accumulating during childhood. We look forward to discussing the data alongside the extensive evidence supporting low-dose atropine and the clinical experience of physicians who treat children every day.”

Dissecting the STAR Trial and Market Dynamics

The Phase 3 STAR trial stands as the largest vehicle-controlled clinical trial of low-dose atropine conducted in North America and Europe, evaluating 847 children aged 3 to 14. The data reveals a nuanced picture of efficacy that underscores the importance of early intervention.

SYD-101 0.01% successfully met its primary endpoint, significantly reducing the proportion of children experiencing confirmed progression beyond −0.75 D at Month 36 (p=0.0226). It also met its key secondary endpoint, reducing the annual myopia progression rate (p=0.0002). Crucially, the treatment was well-tolerated, with no new safety signals or significant rebound effects identified through a 48-month withdrawal phase.

However, the data's true commercial and clinical value lies in the subgroup analyses. Because approximately 36% of the trial participants aged into their late teens by the study's conclusion—a period when natural myopia progression flattens—the overall cohort effect size was diluted. When isolating the younger cohort (ages 3 to 12) and fast progressors, the efficacy of SYD-101 was magnified dramatically, reducing progression by over 56% at Month 36 compared to the vehicle.

This robust dataset places Sydnexis in a uniquely advantageous market position, particularly as competitors have faltered. Eyenovia's high-profile Phase 3 CHAPERONE trial was terminated in late 2024 after failing its primary endpoint, while Vyluma's NVK002 remains delayed following its own regulatory hurdles. Sydnexis is now the sole entity standing with a validated Phase 3 dataset demonstrating statistical superiority across 36 months.

Global Divergence: Europe Advances While the U.S. Hesitates

As the U.S. regulatory apparatus deliberates, the global commercial landscape is already moving forward. SYD-101 is currently approved in the European Union and the United Kingdom, where it is licensed to Santen S.A. and marketed as Ryjunea®. This international divergence highlights a growing tension in global biopharma: European health authorities have recognized the public health urgency and commercial viability of standardized low-dose atropine, while the U.S. remains bottlenecked by statistical debates.

For frontline clinicians, the stakes could not be higher. The American Medical Association recently resolved to recognize pediatric progressive myopia as a distinct disease entity, urging insurers to cover evidence-based therapeutics. The October Open Public Hearing will allow these frustrated physicians to voice their concerns directly to the FDA panel.

“The goal for clinicians who treat PPM is to intervene and slow progression during the years when a child’s eyes are still developing, as this limited time period is when myopia is most active,” said Rahul Bhola, MD, Medical Director and Chief, Division of Ophthalmology at Children’s Hospital of Orange County. “Low-dose atropine is already used routinely by many pediatric ophthalmologists and optometrists as part of standard clinical practice, but an FDA-approved treatment would give physicians a standardized, rigorously evaluated option. Beyond changing the underlying course of PPM, an approved therapy would also help address the access and consistency challenges often associated with compounded formulations, which is the only option available today in the U.S. I look forward to participating in this advisory committee meeting, where the strength of the STAR trial data can be discussed and real-world clinical perspectives can be heard.”

As October 30 approaches, biotech investors, healthcare policymakers, and global supply chain strategists are watching closely. The FDA's decision will not only dictate the commercial fate of Sydnexis but will also set a crucial precedent for how the U.S. healthcare system manages the transition from localized compounding to regulated pharmaceutical intervention in the face of a mounting global health crisis.